Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Icotrokinra (JNJ-2113), the first-ever oral IL-23 receptor antagonist developed in collaboration with Johnson & Johnson, which has shown substantial efficacy in multiple Phase 3 trials for ...